Therefore, anti-CSCs ability of LECT2 implicates that LECT2-based therapy may constitute an adjuvant therapy in conjunction with the current first-line HCC drugs such as doxorubicin and sorafenib. Here, LECT2 is linked to hepatocellular carcinoma.